EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma

Gujie Wu, Qin Hu, Hongyu Chen, Min He, Huiyun Ma, Lin Zhou, Kun Xu, Hefei Ren, Juntao Qi

Frontiers in Oncology · 15.03.2023 · 13

DOI: 10.3389/fonc.2023.1127768 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 15.03.2023. Verfasst von Gujie Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cuproptosis is a novel form of programmed cell death that disrupts the tricarboxylic acid (TCA) cycle and mitochondrial function. The mechanism of cuproptosis is quite different from that of common forms of cell death such as apoptosis, pyroptosis, necroptosis, and ferroptosis. However, the potential connection between cuproptosis and tumor immunity, especially in lung adenocarcinoma (LUAD), is poorly understood.

Methods

We used machine learning algorithms to develop a cuproptosis-related scoring system. The immunological features of the scoring system were investigated by exploring its association with clinical outcomes, immune checkpoint expression, and prospective immunotherapy response in LUAD patients. The system predicted the sensitivity to chemotherapeutic agents. Unsupervised consensus clustering was performed to precisely identify the different cuproptosis-based molecular subtypes and to explore the underlying tumor immunity.

Results

We determined the aberrant expression and prognostic relevance of cuproptosis-related genes (CRGs) in LUAD. There were significant differences in survival, biological function, and immune infiltration among the cuproptosis subtypes. In addition, the constructed cuproptosis scoring system could predict clinical outcomes, tumor microenvironment, and efficacy of targeted drugs and immunotherapy in patients with LUAD. After validating with large-scale data, we propose that combining the cuproptosis score and immune checkpoint blockade (ICB) therapy can significantly enhance the efficacy of immunotherapy and guide targeted drug application in patients with LUAD.

Conclusion

The Cuproptosis score is a promising biomarker with high accuracy and specificity for determining LUAD prognosis, molecular subtypes, immune cell infiltration, and treatment options for immunotherapy and targeted therapies for patients with LUAD. It provides novel insights to guide personalized treatment strategies for patients with LUAD.

Schlagwörter

Stichwörter der Autor:innen

cuproptosisimmunotherapylung adenocarcinomaprognosistumor microenvironment

Autor:innen und Institutionen

  • Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
  • Research Center of Clinical Medicine, Shenzhen Hospital of Shanghai University of Traditional Chinese Medicine, Shenzhen, China.
  • Department of Laboratory Medicine, Changzheng Hospital, Naval Medical University, Shanghai, China.

Zitieren

APA

Wu, G., Hu, Q., Chen, H., He, M., Ma, H., Zhou, L., Xu, K., Ren, H., & Qi, J. (2023). Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1127768

Vancouver

Wu G, Hu Q, Chen H, He M, Ma H, Zhou L, et al. Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1127768

BibTeX
@article{Wu2023,
  author = {Wu, Gujie and Hu, Qin and Chen, Hongyu and He, Min and Ma, Huiyun and Zhou, Lin and Xu, Kun and Ren, Hefei and Qi, Juntao},
  title = {Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1127768}
}
Kostenlos starten →